초록 열기/닫기 버튼
Background/Aims: Among borderline resectable pancreaticcancer (BRPC), group B BRPC patients have findings that aresuggestive but not diagnostic of metastasis. In this study, weattempted to validate whether group B could truly be categorizedas a borderline resectable group. Methods: We placedthe BRPC patients into group A or group B. The survival outcomeswere compared between the groups. Results: A totalof 53 patients with pancreatic adenocarcinoma was classifiedas either group A or B borderline resectable. In groupA, 23 (60.5%) of 38 patients underwent pancreatectomyafter concurrent chemoradiotherapy or chemotherapy, but ingroup B, only five (33.3%) of 15 patients underwent pancreatectomy,mainly because of the progression of suspecteddistant metastasis. There was a significant difference inoverall survival (OS) between group A and B patients (medianOS, 21.2 months vs 10.2 months, respectively; p=0.007). Ofthe patients who underwent pancreatectomy, group B hada higher recurrence rate compared to group A (recurrencerate: 11 of 23 patients [47.8%] vs five of five patients [100%],respectively; p=0.033). Conclusions: This report is the firstto validate the definition of BPRC. Group B had much worseoutcomes, and whether group B BRPC can be categorizedas BRPC together with group A is questionable.
